Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orticumab - Abcentra

Drug Profile

Orticumab - Abcentra

Alternative Names: 2D03; Anti-oxLDL; BI-204; MLDL 1278A; RG 7418

Latest Information Update: 27 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International
  • Developer Abcentra; BioInvent International; Genentech
  • Class Anti-inflammatories; Antibodies; Antihyperlipidaemics; Antipsoriatics; Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action Oxidised low density lipoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Atherosclerosis; Psoriasis
  • Preclinical Aortic valve stenosis

Most Recent Events

  • 27 Jun 2019 Preclinical trials in Aortic valve stenosis in USA (Parenteral) before June 2019 (Abcentra pipeline, June 2019)
  • 07 Feb 2019 Abcentra plans phase II trials for Psoriasis and Atherosclerosis
  • 30 Jan 2019 CardioVax is now called Abcentra
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top